Sunday 10 November: 16:30–18:00, B405–B407, Georgia World Congress Center, Atlanta, USA
Presenter: Irene van der Horst-Bruinsma, Amsterdam University Medical Center, the Netherlands
In the C-VIEW trial, patients with active axial spondyloarthritis (ankylosing spondylitis or nonradiographic axial spondyloarthritis) and a recent history of acute anterior uveitis (AAU) flares were given 96 weeks of treatment with certolizumab pegol at a dose of 200 mg every 2 weeks following a loading dose of 400 mg at weeks 0, 2, and 4.
The primary outcome is the incidence of AAU flares during versus before treatment, and van der Horst-Bruinsma will present the 48-week interim results of the study.
What our Advisory Board said:
This is an important analysis for those treating resistant uveitis where certolizumab may have shown efficacy.